Kiniksa Pharmaceuticals Ltd. (KNSA) Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at EULAR

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced an upcoming presentation, entitled Mavrilimumab Improves Outcomes in Severe COVID-19 Pneumonia and Systemic Hyper-Inflammation, showing data from the open-label treatment protocol with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation will be delivered at the European E-Congress of Rheumatology (EULAR) 2020. Additionally, preclinical data analyzing the role of the granulocyte macrophage colony stimulating factor (GM-CSF) pathway in giant cell arteritis (GCA) pathophysiology will be included in a poster presentation.

Professor Lorenzo Dagna, MD, FACP, Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy will deliver an oral presentation of outcomes data from the mavrilimumab treatment protocol in COVID-19 pneumonia and hyperinflammation in Italy.

Oral Presentation Details:

• Abstract #CO0001: Mavrilimumab Improves Outcomes in Severe COVID-19 Pneumonia and Systemic Hyper-Inflammation
• Session: EULAR COVID-19 Recommendations
• Date and Time: Wednesday, June 3, 2020 from; 5:15pm to 5:25pm Central European Time (oral presentation); 4:30pm to 5:35pm Central European Time (full session)
• Lead Authors: Lorenzo Dagna, Giacomo De Luca1,2, Corrado Campochiaro1,2

There will also be a presentation of preclinical data analyzing the role of the GM-CSF pathway in GCA pathophysiology delivered by Dr. Maria C. Cid, MD, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Vasculitis Research Unit, Department of Autoimmune Diseases, Barcelona, Spain.

Poster Presentation Details:

• Abstract #FRI0010: GM-CSFR Pathway is Implicated in Pathogenic Inflammatory Mechanisms in Giant Cell Arteritis
• Session: A Journey into the Innate Immune Mechanisms Driving Rheumatic Diseases and Novel Therapeutic Strategies
• Date and Time: Friday, June 5, 2020 from 11:50am to 1:30pm Central European Time
• Lead Authors: Maria C. Cid, Sujatha Muralidharan3, Marc Corbera-Bellalta4

Kiniksa intends to make the presentations available through the Science section of Kiniksa’s website (www.kiniksa.com) after the EULAR embargo lifts, which is expected to be at the time of each presentation.

1IRCCS San Raffaele Scientific Institute, Milan, Italy; 2Vita-Salute San Raffaele University, Milano, Italy; 3Kiniksa Pharmaceuticals, Lexington, United States of America; 4Vasculitis Research Unit, Hospital Clinic, University of Barcelona, IDIBAPS.

You May Also Be Interested In

• Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance
• Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287
• Amphenol (APH) Reports Q1, Announces $2B Share Buyback